187 related articles for article (PubMed ID: 33289952)
1. PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.
Takita H; Barnett S; Zhang Y; Ménochet K; Shen H; Ogungbenro K; Galetin A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):137-147. PubMed ID: 33289952
[TBL] [Abstract][Full Text] [Related]
2. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
[TBL] [Abstract][Full Text] [Related]
3. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
4. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
5. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
6. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.
Takita H; Scotcher D; Chu X; Yee KL; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2022 Sep; 112(3):615-626. PubMed ID: 35652251
[TBL] [Abstract][Full Text] [Related]
7. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
8. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
[TBL] [Abstract][Full Text] [Related]
10. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
12. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
[TBL] [Abstract][Full Text] [Related]
13. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
Gertz M; Tsamandouras N; Säll C; Houston JB; Galetin A
Pharm Res; 2014 Sep; 31(9):2367-82. PubMed ID: 24623479
[TBL] [Abstract][Full Text] [Related]
14. Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers.
Neuvonen M; Hirvensalo P; Tornio A; Rago B; West M; Lazzaro S; Mathialagan S; Varma M; Cerny MA; Costales C; Ramanathan R; Rodrigues AD; Niemi M
Clin Pharmacol Ther; 2021 Mar; 109(3):646-657. PubMed ID: 32961594
[TBL] [Abstract][Full Text] [Related]
15. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
16. Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.
Suzuki Y; Sasamoto Y; Koyama T; Yoshijima C; Nakatochi M; Kubo M; Momozawa Y; Uehara R; Ohno K
Clin Transl Sci; 2021 Jan; 14(1):382-388. PubMed ID: 32961019
[TBL] [Abstract][Full Text] [Related]
17. Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans.
Neuvonen M; Tornio A; Hirvensalo P; Backman JT; Niemi M
Clin Pharmacol Ther; 2021 Dec; 110(6):1622-1632. PubMed ID: 34580865
[TBL] [Abstract][Full Text] [Related]
18. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
[TBL] [Abstract][Full Text] [Related]
19. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
[TBL] [Abstract][Full Text] [Related]
20. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).
Lee HH; Ho RH
Br J Clin Pharmacol; 2017 Jun; 83(6):1176-1184. PubMed ID: 27936281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
